生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Osimertinib mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible EGFR inhibitor selective for mutant forms, with an IC50 of 12 nM against the L858R mutation and 1 nM against the L858R/T790M mutation. Otherwise, Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.68mL 0.34mL 0.17mL |
8.39mL 1.68mL 0.84mL |
16.79mL 3.36mL 1.68mL |
参考文献 |
---|